HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China

04 2 2022 04:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China

19 1 2022 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium

18 1 2022 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia

12 1 2022 06:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China

09 1 2022 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Included in FTSE Russell Indexes

19 12 2021 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meeting

14 12 2021 00:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 Meeting

10 12 2021 05:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer

05 12 2021 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition of SULANDA® in the National Reimbursement Drug List in China

03 12 2021 00:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy

23 11 2021 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting

07 11 2021 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma

01 11 2021 00:15:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China

27 10 2021 20:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Oral Presentations at 2021 Chinese Society of Clinical Oncology Annual Meeting

28 9 2021 20:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Closing of Divestment of Non-Core OTC Joint Venture

28 9 2021 20:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in China

20 9 2021 20:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors

19 9 2021 20:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma

13 9 2021 02:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

08 9 2021 06:30:00 提供 Nasdaq GlobeNewswire